The new Ambizione fellow Dr. Florent Waltz , project leader in Prof. Ben Engel’s team, will study the molecular architecture of mitochondria and their interaction with chloroplasts, the site of photosynthesis, in more…
In response to last year’s call for SNSF Advanced Grants 232 researchers submitted applications. 24 of these projects were awarded the Swiss National Science Foundation grant, totaling 50 million Swiss francs in funding.…
It was only at the beginning of the year that the Biozentrum spin-off Aukera Therapeutics qualified for the BaseLaunch Accelerator program. Now the two young entrepreneurs Dr. Stefan Imseng and Dr. Dritan Liko can add…
The Ambizione fellow Dr. Janani Durairaj , project leader in the research group of Prof. Torsten Schwede, will study the protein universe of viruses in more detail. Viruses have evolved diverse pathogenic mechanisms and…
The objectives of the National Center of Competence in Research (NCCR) "AntiResist" are to search for new antibiotics and to develop alternative strategies to combat antibiotic-resistant pathogens. "AntiResist" is one of a…
The Biozentrum start-up Aukera Therapeutics was selected to join the BaseLaunch Accelerator Program. With its qualification for this program, the biotech venture receives funding of up to 500,000 Swiss francs as well as…
A number of pathogens protect themselves with an outer membrane that makes it difficult to combat them with antibiotics. In addition, the widespread use of antibiotics promotes the development of resistant bacteria. In…
The distinguished jury announced that Prof. Marek Basler from the Biozentrum, University of Basel, will receive the Sanofi-Institut Pasteur International Junior Award this year together with Prof. Ido Amit, Weizmann…
Michael N. Hall receives the Balzan Prize for his groundbreaking contributions to our understanding of the molecular mechanisms that regulate cell growth and ageing. Michael Hall discovered two proteins, TOR1 and TOR2, which…
According to T3 Pharmaceuticals (T3 Pharma), the funds of more than 25 million Swiss francs will be used primarily to progress the lead candidate through early clinical studies. The clinical trial in patients with solid…
This website uses cookies to collect data from users and improve functionality. By continuing to browse the site you are agreeing to this. Receive more information by reading our privacy policy.
